Endometrial cancer is the most common gynecologic cancer in the United States. While many cases are diagnosed early and treated successfully, metastatic endometrial cancer remains difficult to treat once it spreads beyond the uterus. Researchers continue to search for more effective therapies, especially for patients whose cancer has stopped responding to standard treatments.
A recently published case report highlights a potentially important breakthrough. The study described an exceptional response to trastuzumab deruxtecan (T-DXd) in a patient with HER2-positive metastatic endometrial cancer, suggesting that a targeted treatment strategy already used in other cancers may have an important role in some endometrial cancer patients.
What Does HER2-Positive Mean?
HER2 stands for human epidermal growth factor receptor 2, a protein found on the surface of some cancer cells. When too much HER2 is present, cancer cells can grow and spread more quickly.
HER2 is best known for its role in certain breast cancers, but researchers have also found HER2 overexpression in some aggressive forms of endometrial cancer, particularly high-grade tumors.
Identifying HER2-positive disease is important because it creates an opportunity to use targeted treatments that specifically attack cancer cells carrying this protein.
What Is the Antibody-Drug Conjugate T-DXd?
Trastuzumab deruxtecan (T-DXd), also known by the brand name Enhertu, is a type of treatment called an antibody-drug conjugate. This means it combines two therapies into one.
The treatment includes:
- Trastuzumab, a targeted antibody that seeks out HER2-positive cancer cells
- Deruxtecan, a powerful chemotherapy payload attached to the antibody
The antibody acts like a delivery system. It finds HER2-positive cancer cells and delivers chemotherapy directly to them, helping reduce damage to healthy tissues while increasing the treatment’s effect on the tumor.
Why This Case Is Getting Attention
The patient described in the report had metastatic HER2-positive endometrial cancer that had progressed despite multiple previous treatments.
After starting T-DXd, the patient experienced a dramatic and durable response. Tumors shrank significantly, and disease control was maintained longer than would typically be expected in heavily pretreated metastatic endometrial cancer.
Although a single case report cannot prove that a treatment works for everyone, exceptional responses like this often attract attention because they can point researchers toward new treatment strategies that deserve larger clinical trials.
In cancer research, many major advances begin with a small number of patients who respond far better than expected.
Why This Could Be Important for Endometrial Cancer
Historically, treatment options for recurrent or metastatic endometrial cancer have been limited once standard chemotherapy stops working.
The success of T-DXd in this case highlights several important developments:
- The growing importance of precision medicine
- The value of testing tumors for HER2 expression
- The possibility of using targeted therapies instead of relying only on traditional chemotherapy
- New hope for patients with aggressive forms of endometrial cancer
The findings also support the idea that endometrial cancer should not be viewed as a single disease. Different tumors can have different genetic features, and those differences may help determine which treatments work best.
What Comes Next?
Researchers are already studying T-DXd in a variety of HER2-positive cancers. This case adds to growing interest in evaluating the drug more broadly in gynecologic cancers, including endometrial cancer.
Future clinical trials will be needed to determine:
- Which endometrial cancer patients benefit most
- How long responses typically last
- Whether T-DXd should be used earlier in treatment
- How it compares with existing therapies
This is a single patient case report. Research studies are needed to confirm these early findings, HER2 testing could become even more important for patients with advanced endometrial cancer.
The Bottom Line
The exceptional response reported in this case represents an encouraging step forward in the treatment of HER2-positive metastatic endometrial cancer. While more research is needed, the results suggest that targeted therapies such as trastuzumab deruxtecan may offer new hope for patients facing advanced disease.
As precision medicine continues to evolve, treatments designed around the unique biology of a tumor may help improve outcomes and create more personalized options for women with endometrial cancer.
Source:
Fader AN, et al. Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer. Case Rep Oncol. 2025;18:1027-1034. Accessed by: https://pmc.ncbi.nlm.nih.gov/articles/PMC12651274/
